• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Anderson, Heather
    Scarffe, J Howard
    Lambert, M
    Smith, David B
    Chan, C C
    Chadwick, G
    McMahon, A
    Chang, James
    Crowther, Derek
    Swindell, Ric
    Affiliation
    CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
    Issue Date
    1987
    
    Metadata
    Show full item record
    Abstract
    Thirty-three patients with multiple myeloma (11 untreated, 15 refractory and seven relapsed patients) have received vincristine and adriamycin infusion therapy with oral dexamethasone (VAD). The median number of course received was five. In addition 16 patients with lymphoid malignancy have received a median of four courses of VAD. Three patients who relapsed after VAD have received further VAD therapy making 52 patient treatments assessable for toxicity. Ten per cent had nausea, 4 per cent vomiting, 4 per cent total alopecia, 25 per cent constipation, 33 per cent paraesthesiae, 8 per cent proximal myopathy, 33 per cent dyspepsia, 23 per cent proven bacteraemia, and 19 per cent chest infections. Infections were not usually associated with neutropenia. Shingles was seen in four patients with myeloma, but none of the patients with lymphoid malignancy. The response rate in myeloma was 9/11, for previously untreated patients, 3/7 for relapsed, and 8/15 for refractory patients. Responses have been seen in other lymphoid malignancies-1/2 patients with relapsed acute lymphoblastic leukaemia had a complete remission. Two out of seven patients with chronic lymphocytic leukaemia achieved a partial remission, and a further three had a clinical improvement. Three out of six patients with non-Hodgkin lymphoma and one patient with macroglobulinaemia achieved a partial remission.
    Citation
    VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies., 5 (3):213-22 Hematol Oncol
    Journal
    Hematological Oncology
    URI
    http://hdl.handle.net/10541/114695
    DOI
    10.1002/hon.2900050308
    PubMed ID
    3115884
    Type
    Article
    Language
    en
    ISSN
    0278-0232
    ae974a485f413a2113503eed53cd6c53
    10.1002/hon.2900050308
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    • Authors: Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P
    • Issue date: 1996 Nov-Dec
    • [The efficacy of VAD chemotherapy for refractory lymphoid malignancies].
    • Authors: Gotoh H, Oku N, Inaba T, Murakami S, Oku N, Takeda N, Itoh K, Fujita N, Ura Y, Nakanishi S
    • Issue date: 1991 Aug
    • [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    • Authors: Luo SK, Li J, Hong WD, Zhao Y, Tong XZ
    • Issue date: 2005 Dec
    • [Treatment of refractory multiple myeloma with vincristine, adriamycin, and dexamethasone].
    • Authors: Ma MX, Yiu JR, Wu SL
    • Issue date: 1989 May
    • Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    • Authors: Browman GP, Belch A, Skillings J, Wilson K, Bergsagel D, Johnston D, Pater JL
    • Issue date: 1992 Nov
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.